已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

作者
Jadwiga A. Wedzicha,Donald Banerji,Kenneth R. Chapman,Jørgen Vestbo,Nicolás Roche,R. Timothy Ayers,Chau Thach,Robert Fogel,Francesco Patalano,Claus Vogelmeier
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:374 (23): 2222-2234 被引量:877
标识
DOI:10.1056/nejmoa1516385
摘要

BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear. METHODS: We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations. RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exacerbations; the rate was 11% lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95% confidence interval [CI], 0.83 to 0.96; P=0.003). The indacaterol-glycopyrronium group had a longer time to the first exacerbation than did the salmeterol-fluticasone group (71 days [95% CI, 60 to 82] vs. 51 days [95% CI, 46 to 57]; hazard ratio, 0.84 [95% CI, 0.78 to 0.91], representing a 16% lower risk; P<0.001). The annual rate of moderate or severe exacerbations was lower in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (0.98 vs. 1.19; rate ratio, 0.83; 95% CI, 0.75 to 0.91; P<0.001), and the time to the first moderate or severe exacerbation was longer in the indacaterol-glycopyrronium group than in the salmeterol-fluticasone group (hazard ratio, 0.78; 95% CI, 0.70 to 0.86; P<0.001), as was the time to the first severe exacerbation (hazard ratio, 0.81; 95% CI, 0.66 to 1.00; P=0.046). The effect of indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was independent of the baseline blood eosinophil count. The incidence of adverse events and deaths was similar in the two groups. The incidence of pneumonia was 3.2% in the indacaterol-glycopyrronium group and 4.8% in the salmeterol-fluticasone group (P=0.02). CONCLUSIONS: Indacaterol-glycopyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerbation during the previous year. (Funded by Novartis; FLAME ClinicalTrials.gov number, NCT01782326.).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
巧巧发布了新的文献求助10
1秒前
2秒前
3秒前
lililili发布了新的文献求助10
3秒前
cc发布了新的文献求助10
5秒前
wan的应助被耍酷大山采纳,获得10
5秒前
gyq发布了新的文献求助10
5秒前
传奇3的应助被耍酷大山采纳,获得10
5秒前
科研通AI65的应助被耍酷大山采纳,获得10
5秒前
科研通AI6.4的应助被耍酷大山采纳,获得10
5秒前
sw123完成签到 ,获得积分10
5秒前
科研通AI6.2的应助被耍酷大山采纳,获得10
5秒前
科研通AI6.3的应助被耍酷大山采纳,获得10
6秒前
星辰大海的应助被耍酷大山采纳,获得10
6秒前
Maestro_S的应助被耍酷大山采纳,获得10
6秒前
Maestro_S的应助被耍酷大山采纳,获得10
6秒前
6秒前
7秒前
喜哦肖完成签到,获得积分10
8秒前
赵师傅发布了新的文献求助10
8秒前
完美世界的应助被M1采纳,获得10
8秒前
8秒前
等待的莹芝完成签到 ,获得积分10
9秒前
9秒前
fortuna完成签到 ,获得积分10
10秒前
10秒前
10秒前
keke发布了新的文献求助10
11秒前
11秒前
Xoosi完成签到 ,获得积分10
11秒前
kita完成签到 ,获得积分10
11秒前
11秒前
Owen的应助被u511277采纳,获得10
12秒前
云蓝完成签到 ,获得积分10
12秒前
13秒前
智慧女孩不秃头完成签到,获得积分10
13秒前
喜哦肖发布了新的文献求助10
13秒前
搜集达人的应助被Senna采纳,获得10
13秒前
Owen的应助被u511277采纳,获得10
13秒前
liurong发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194612
求助须知:如何正确求助?哪些是违规求助? 9580394
关于积分的说明 21870930
捐赠科研通 7794182
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484411